Another Innovative Therapy for Myasthenia Gravis Achieves Breakthrough, NDA Filing Planned

　　【Pharmaceutical Network Industry DynamicsMyasthenia Gravis: A Rare Neuroimmune Disorder
 

As announced by RemeGen on the evening of August 13, the Phase III clinical trial of the company's self-developed innovative drug Telitacicept (RC18, trade name: Tai'ai®), a BLyS/APRIL dual-target fusion protein for treating generalized myasthenia gravis (gMG), has achieved the primary endpoint designed in the clinical trial protocol.
 

Clinical research results show that Telitacicept can continuously and effectively improve the clinical symptoms of patients with generalized myasthenia gravis, demonstrating good efficacy and safety. The company will seize the opportunity to submit an application for marketing authorization to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
 

RemeGen introduced that this is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy and safety of Telitacicept in treating patients with generalized myasthenia gravis. Clinical research results show that Telitacicept can continuously and effectively improve the clinical condition of patients with generalized myasthenia gravis. It was reported that on August 5, RemeGen also announced the enrollment of the first patient in the United States for its global multi-center Phase III clinical trial for myasthenia gravis indication. Currently, Telitacicept has received three designations in the field of myasthenia gravis: Breakthrough Therapy designation from the China National Medical Products Administration, Orphan Drug and Fast Track designations from the U.S. FDA.
 

IASO Bio's self-developed fully human anti-BCMA chimeric antigen receptor autologous T-cell injection (Equecabtagene Autoleucel Injection) received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in early 2024 for its expanded indication to include refractory generalized myasthenia gravis in clinical trials.
 

According to industry sources, the injectable Ixazomib (trade name: Fokosu®) was approved for marketing by the National Medical Products Administration on June 30, 2023, for the treatment of relapsed and refractory multiple myeloma. The recent approval of the IND for severe myasthenia gravis further expands the indications for the injectable Ixazomib.
 

IASO Biotherapeutics stated that, for a long time, the treatment of patients with generalized myasthenia gravis (MG) has mainly relied on expert experience and traditional treatment methods. Existing drug therapies are not effective for all patients, and clinically, 10%-15% of MG patients suffer from refractory disease. The treatment of these refractory MG patients and those potentially at risk of developing a crisis poses a significant clinical challenge, urgently requiring safe and effective innovative treatments to address these issues. The company expressed that it is pleased to see in its investigator-initiated trial (IIT) that the injection of Equecabtagene Autoleucel can halt disease progression and shows early signs of reversing the disease, which is expected to transform the treatment landscape for MG. IASO Bio will expedite the initiation and completion of clinical trials to bring hope of a cure to Chinese patients with severe myasthenia gravis.
 

In addition, according to the review, efgartigimod, introduced by Zai Lab from Argenx, is currently the only FcRn antagonist approved for marketing in China and is also the FcRn antagonist reimbursable by medical insurance in China. It is used to treat adult patients with generalized myasthenia gravis who are positive for acetylcholine receptor (AChR) antibodies.
 

In March 2023, HBM published the Phase III trial data of Batoclimab for the treatment of generalized myasthenia gravis (gMG), which showed that the study had reached the primary endpoint and key secondary endpoints. Meanwhile, the treatment was generally safe and well-tolerated without new safety signals detected. However, in December 2023, HBM suddenly announced the delay of the Phase III clinical trial of Batoclimab to collect other long-term safety data, withdrew the drug’s marketing application, and planned to resubmit it in 2024.
 

Experts in the field indicate that traditional treatment methods for myasthenia gravis patients have significant shortcomings in symptom control and treatment side effects. For a long time, achieving dual therapeutic goals has been very difficult, which is also the current challenge in treating myasthenia gravis. Therefore, there is an urgent need for safe and effective innovative therapies for myasthenia gravis.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.